Is Silexion Therapeutics Corp (SLXN) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 77.9% / 30% | 20.6% / 30% | 0.0% / 30% | N/A | ✗ NOT HALAL |
| DJIM | 77.9% / 33% | 20.6% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| MSCI | 156.9% / 33% | 41.5% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| S&P | 77.9% / 33% | 20.6% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| FTSE | 156.9% / 33% | 41.5% / 33% | 0.0% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Assets (ROA) | -144.3% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$8M |
| Free Cash Flow | -$8M |
| Total Debt | $4M |
| Debt-to-Equity | 78.2 |
| Current Ratio | 2.4 |
| Total Assets | $3M |
Price & Trading
| Last Close | $1.27 |
| 50-Day MA | $1.71 |
| 200-Day MA | $4.95 |
| Avg Volume | 40K |
| Beta | -0.0 |
|
52-Week Range
$1.07
| |
About Silexion Therapeutics Corp (SLXN)
Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. Silexion Therapeutics Corp has collaboration with Evonik Corporation for the development of an advanced siRNA formulation to enhance cancer treatment. The company was founded in 2008 and is headquartered in Jerusalem, Israel.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Silexion Therapeutics Corp (SLXN) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Silexion Therapeutics Corp is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Silexion Therapeutics Corp's debt ratio?
Silexion Therapeutics Corp's debt ratio is 77.9% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 156.9%.
What are Silexion Therapeutics Corp's key financial metrics?
Silexion Therapeutics Corp has a market capitalization of $4M.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.